Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant breast-cancer trial

By Mansi Janine  

The Women's Oncology Review, Vol. 5, Iss. 3, 2005-09 ,pp. : 161-162

Informa Healthcare

Access to resources Recommend Favorite

The ATAC (Arimidex&unknown;, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment

By Baum M.  

European Journal of Cancer, Vol. 38, Iss. 15, 2002-10 ,pp. : 1984-1986

Elsevier

Access to resources Recommend Favorite

Breast surgery in the ‘Arimidex, Tamoxifen alone or in combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

By  

The Women's Oncology Review, Vol. 4, Iss. 4, 2004-12 ,pp. : 305-306

Informa Healthcare

Access to resources Recommend Favorite

Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial

By Thürlimann Beat   Hess Dagmar   Köberle Dieter   Senn Isabella   Ballabeni Pierluigi   Pagani Olivia   Perey Lucien   Aebi Stefan   Rochlitz Christoph   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 85, Iss. 3, 2004-06 ,pp. : 247-254

Springer Publishing Company

Access to resources Recommend Favorite